| Product ID | 68180-286_1b400ffe-d764-45a1-9e79-5ec9359ba856 |
| NDC | 68180-286 |
| Product Type | Human Prescription Drug |
| Proprietary Name | ABACAVIR, LAMIVUDINE AND ZIDOVUDINE |
| Generic Name | Abacavir , Lamivudine And Zidovudine |
| Dosage Form | Tablet |
| Route of Administration | ORAL |
| Marketing Start Date | 2013-12-17 |
| Marketing Category | ANDA / ANDA |
| Application Number | ANDA202912 |
| Labeler Name | Lupin Pharmaceuticals, Inc. |
| Substance Name | LAMIVUDINE; ZIDOVUDINE; ABACAVIR SULFATE |
| Active Ingredient Strength | 150 mg/1; mg/1; mg/1 |
| Pharm Classes | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |